GENERAL
Sun Pharmaceutical Agrees To MFN Pricing For US Medicaid Programmes
Sun Pharmaceutical Industries has joined several pharmaceutical companies in announcing agreements with the US government aimed at prioritising access to affordable medicines for millions of American patients. Under its agreement, Sun Pharma will extend Most Favoured Nation (MFN) pricing to state Medicaid programmes. The company has also committed to MFN pricing for future innovative medicine […]
CW Bureau
·
Sep 1, 2026
GENERAL
Biocon Biologics Secures Japan Govt Approval For Pegfilgrastim Biosimilar
Biocon Biologics Ltd, a wholly owned subsidiary of Biocon Ltd., has received marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its pegfilgrastim biosimilar, strengthening the company’s biosimilars portfolio in the Japanese market. The product is a biosimilar to Neulasta, a pegfilgrastim-based medicine used to reduce the risk of infection associated with […]
CW Bureau
·
Aug 25, 2026
GENERAL
Amneal Pharma Completes Kashiv Bio Buy, Strengthens Biosimilars Platform
Amneal Pharmaceuticals Inc. has completed its acquisition of Kashiv BioSciences LLC, creating a fully integrated global biosimilars platform with capabilities spanning research, development, manufacturing and commercialisation. The acquisition brings together Kashiv’s biologics research, development and manufacturing capabilities with Amneal’s commercial scale, positioning biosimilars as a major long-term growth pillar for the company’s affordable medicines business. […]
CW Bureau
·
Aug 11, 2026
GENERAL
After 90 Years Of ‘Caring For Life’, Cipla Charts Innovative Journey Path
Ninety years ago, Mumbai headquartered Cipla Ltd, began with a mission to make medicines affordable and accessible for Indians. What started as a commitment to self-reliance in pharmaceuticals has evolved into a global healthcare enterprise serving millions of patients across markets. As Cipla celebrates 90 years of its journey, the company is looking ahead with […]
CW Bureau
·
Jun 2, 2026
GENERAL
Glenmark Pharma Launches Generic Vancomycin Injection In US Market
Glenmark Pharmaceuticals has announced the launch of Vancomycin Hydrochloride for Injection USP in the U.S. market, expanding its injectable portfolio amid growing demand for affordable hospital medicines. The company said the product will be available in 500 mg/vial and 1 g/vial strengths through its U.S.-based arm, Glenmark Pharmaceuticals Inc., USA. Targets $37.9 million market opportunity […]
CW Bureau
·
May 18, 2026
